Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Exicure, Inc. (XCUR)
USD1.62
-0.10 (-5.81%)
US NASDAQ Healthcare Biotechnology
Address
2430 North Halsted Street 60614
Chicago, IL, US
Chicago, IL, US
CEO
Jungsoo Kim
Website
exicuretx.com
IPO
2018-05-22
CIK 1698530 ISIN US30205M3097
Description
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.62
-0.10 (-5.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
23.7K
Beta
3.54
Float Shares
1.79M
Free Float %
28.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.41% | +16.00% | -5.06% | -14.71% | -23.68% | -41.14% | -69.50% | -27.66% | -98.76% | -99.31% | -99.31% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
1.62
Low
12.00
+640.7%
Consensus
12.00
+640.7%
Median
12.00
+640.7%
High
12.00
+640.7%
DCF (Unlevered)
0.35
-78.2%
DCF (Levered)
0.57
-65.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
12.00
+640.7%
|
Quality scores
Altman Z-Score
-23.84
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+50.3% ★ Q1'26: -159.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-2,841.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.2% ★ Q1'26: +3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
118.0K
est: 112.0K (+5.4%)
|
1.30M
est: 1.07M (+21.3%)
|
16.61M
est: 18.96M (-12.4%)
|
-483.0K
est: 900.0K (-153.7%)
|
28.83M
est: 12.80M (+125.2%)
|
—
est: 16.68M (-100.0%)
|
500.0K
est: 28.91M (-98.3%)
|
—
est: 63.16M (-100.0%)
|
| EBITDA |
-21.38M
est: 60.00 (-35,638,433.3%)
|
-24.79M
est: 577.00 (-4,296,980.4%)
|
-22.65M
est: 10.3K (-220,883.8%)
|
-60.63M
est: 487.00 (-12,450,202.7%)
|
78.0K
est: 6.9K (+1,026.0%)
|
-15.54M
est: 9.0K (-172,220.1%)
|
-8.85M
est: 11.58M (-176.4%)
|
-9.66M
est: 25.30M (-138.2%)
|
| EBIT |
-21.74M
est: -1.4K (-1,574,194.0%)
|
-25.52M
est: -13.2K (-193,592.1%)
|
-24.10M
est: -233.8K (-10,204.1%)
|
-62.41M
est: -11.1K (-562,060.0%)
|
-1.78M
est: -157.9K (-1,026.0%)
|
-16.91M
est: -205.8K (-8,118.6%)
|
-9.68M
est: 11.21M (-186.3%)
|
-10.12M
est: 24.48M (-141.3%)
|
| Net Income |
-22.41M
est: -540.27M (+95.9%)
|
-26.30M
est: -375.44M (+93.0%)
|
-24.67M
est: -217.94M (+88.7%)
|
-64.10M
est: -650.16M (+90.1%)
|
-2.58M
est: -146.82M (+98.2%)
|
-16.91M
est: -677.63M (+97.5%)
|
-9.70M
est: -698.98M (+98.6%)
|
-4.95M
est: -491.17M (+99.0%)
|
| SGA |
7.82M
est: -318.5K (+2,554.4%)
|
8.57M
est: -3.04M (+382.2%)
|
9.96M
est: -53.91M (+118.5%)
|
13.09M
est: -2.56M (+611.3%)
|
10.89M
est: -36.40M (+129.9%)
|
12.65M
est: -47.45M (+126.7%)
|
5.45M
est: -79.89M (+106.8%)
|
6.83M
est: -174.56M (+103.9%)
|
| EPS |
-16.32
est: -88.50 (+81.6%)
|
-13.68
est: -61.50 (+77.8%)
|
-8.49
est: -35.70 (+76.2%)
|
-21.70
est: -106.50 (+79.6%)
|
-0.56
est: -24.05 (+97.7%)
|
-2.11
est: -111.00 (+98.1%)
|
-1.59
est: -111.00 (+98.6%)
|
-0.79
est: -78.00 (+99.0%)
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-8.10M
OE per share TTM
-1.28
Owner's Yield
-39.83%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
93.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
17
Total invested
687.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chad A. Mirkin, Ph.D. | 11.38M | 32.00% | 112.5K | 11.27M | 112.5K | 10.00 | IN | United States of America | 2017-10-06 | ↗ |
| 2 | Colby Shad Thaxton, M.D., Ph.D. | 11.35M | 31.90% | 83.3K | 11.27M | 83.3K | 10.00 | OO | United States of America | 2017-10-06 | ↗ |
| 3 | AuraSense, LLC | 11.27M | 31.70% | — | 11.27M | — | 10.00 | PN | Delaware | 2017-10-06 | ↗ |
| 4 | Armistice Capital, LLC | 11.12M | 9.99% | — | 11.12M | — | 11.12M | IA, OO | — | 2022-02-15 | ↗ |
| 5 | Steven Boyd | 11.12M | 9.99% | — | 11.12M | — | 11.12M | HC, IN | — | 2022-02-15 | ↗ |
| 6 | Gates Ventures, LLC | 6.33M | 17.80% | 6.33M | — | 6.33M | — | OO | State of Washington | 2017-10-05 | ↗ |
| 7 | William H. Gates III | 6.33M | 17.80% | 6.33M | — | 6.33M | — | IN | United States of America | 2017-10-05 | ↗ |
| 8 | Abingworth Bioventures VII, LP 93-1331173 | 6.25M | 8.20% | — | — | — | — | PN | England | 2019-08-09 | ↗ |
| 9 | Abingworth LLP 98-0518585 | 6.25M | 8.20% | — | — | — | — | PN | England | 2019-08-09 | ↗ |
| 10 | Tybourne Capital Management (HK) Limited | 6.25M | 8.23% | — | 6.25M | — | 10.00 | IA | Delaware | 2019-08-12 | ↗ |
| 11 | Tybourne Capital Management Limited | 6.25M | 8.23% | — | 6.25M | — | 10.00 | HC | Cayman Islands | 2019-08-12 | ↗ |
| 12 | Tybourne Kesari Limited | 6.25M | 8.23% | — | 6.25M | — | 10.00 | HC | Cayman Islands | 2019-08-12 | ↗ |
| 13 | Viswanathan Krishnan | 6.25M | 8.23% | — | 6.25M | — | 10.00 | HC, IN | United Kingdom | 2019-08-12 | ↗ |
| 14 | EcoR1 Capital, LLC | 5.95M | 11.00% | — | 5.95M | — | 5.95M | OO | Delaware | 2019-10-07 | ↗ |
| 15 | Oleg Nodelman | 5.95M | 11.00% | — | 5.95M | — | 5.95M | IN | United States | 2019-10-07 | ↗ |
| 16 | W. Lawrence Hawkins | 4.98M | 5.70% | 77.2K | 4.91M | 77.2K | 4.91M | HC, IN | Delaware | 2021-08-20 | ↗ |
| 17 | EcoR1 Capital Fund Qualified, L.P. | 4.95M | 11.00% | — | 4.95M | — | 4.95M | PN | Delaware | 2019-10-07 | ↗ |
| 18 | Prosight Management, LP | 4.91M | 5.60% | — | 4.91M | — | 4.91M | IA | Delaware | 2021-08-20 | ↗ |
| 19 | Prosight Partners, LLC | 4.91M | 5.60% | — | 4.91M | — | 4.91M | OO | Delaware | 2021-08-20 | ↗ |
| 20 | Prosight Plus Fund, LP | 1.88M | 2.10% | — | 1.88M | — | 1.88M | PN | Delaware | 2021-08-20 | ↗ |
| 21 | Prosight Fund, LP | 1.04M | 1.20% | — | 1.04M | — | 1.04M | PN | Delaware | 2021-08-20 | ↗ |
| 22 | CBI USA, Inc. | 818.3K | 16.50% | 818.3K | — | 818.3K | — | CO | — | 2022-12-05 | ↗ |
| 23 | HiTron Systems Inc. | 433.3K | 16.60% | 433.3K | — | 433.3K | — | CO | — | 2024-11-29 | ↗ |
| 24 | Asgard Investment Corp. II | 250.0K | 5.00% | — | 250.0K | — | 250.0K | CO | Cayman Islands | 2022-12-06 | ↗ |
| 25 | Carlson Capital, L.P. | 250.0K | 5.00% | — | 250.0K | — | 250.0K | IA, PN | Cayman Islands | 2022-12-06 | ↗ |
| 26 | Clint D. Carlson | 250.0K | 5.00% | — | 250.0K | — | 250.0K | IN | Cayman Islands | 2022-12-06 | ↗ |
| 27 | Double Black Diamond Offshore Ltd. | 250.0K | 5.00% | — | 250.0K | — | 250.0K | CO | Cayman Islands | 2022-12-06 | ↗ |
| 28 | Paul Tompkins | 183.0K | 0.50% | 183.0K | — | 183.0K | — | IN | Canada | 2017-10-18 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
17
+2 vs prev Q
New positions
5
Closed positions
3
Increased
8
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CARLYLE GROUP INC. | 56.3K -225.3K (-80.0%) | 304.7K -821.8K (-72.9%) | 0.89% -3.567 pp | 0.00% -0.024 pp | USD11.63 -53.4% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 42.0K +— (+0.0%) | 227.9K +55.9K (+32.5%) | 0.67% -0.001 pp | 0.00% +0.000 pp | USD8.90 -39.1% | 4 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 29.8K +445.0 (+1.5%) | 161.4K +41.4K (+34.5%) | 0.47% +0.007 pp | 0.00% +0.000 pp | USD10.14 -46.5% | 5 qtrs — |
| 4 | NORTHERN TRUST CORP | 10.7K +10.7K (+100.0%) | 57.9K +57.9K (+100.0%) | 0.17% +0.169 pp | 0.00% +0.000 pp | USD5.42 +0.0% | 1 qtrs NEW |
| 5 | BLACKROCK, INC. | 4.2K -1.6K (-27.2%) | 22.6K -816.0 (-3.5%) | 0.07% -0.025 pp | 0.00% +0.000 pp | USD5.64 -3.9% | 6 qtrs — |
| 6 | MORGAN STANLEY | 3.6K +1.5K (+73.5%) | 19.3K +10.9K (+129.9%) | 0.06% +0.024 pp | 0.00% +0.000 pp | USD4.55 +19.1% | 6 qtrs — |
| 7 | UBS GROUP AG | 1.4K -17.3K (-92.3%) | 7.9K -68.6K (-89.7%) | 0.02% -0.273 pp | 0.00% +0.000 pp | USD6.96 -22.1% | 6 qtrs — |
| 8 | TOWER RESEARCH CAPITAL LLC (TRC) | 103.00 -1.9K (-94.9%) | 558.00 -7.8K (-93.3%) | 0.00% -0.031 pp | 0.00% 0.000 pp | USD5.63 -3.7% | 6 qtrs — |
| 9 | SBI SECURITIES CO., LTD. | 43.00 +— (+0.0%) | 233.00 +57.0 (+32.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.40 -52.5% | 5 qtrs — |
| 10 | BANK OF AMERICA CORP /DE/ | 39.00 -5.0 (-11.4%) | 211.00 +31.0 (+17.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.74 -19.6% | 6 qtrs — |
| 11 | ADVISOR GROUP HOLDINGS, INC. | 29.00 +— (+0.0%) | 157.00 -5.0 (-3.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.45 +57.1% | 6 qtrs — |
| 12 | PRESTIGE WEALTH MANAGEMENT GROUP LLC | 20.00 +20.0 (+100.0%) | 109.00 +109.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.40 +0.4% | 1 qtrs NEW |
| 13 | BNP PARIBAS ARBITRAGE, SNC | 4.00 +— (+0.0%) | 22.00 +6.0 (+37.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.25 +66.8% | 6 qtrs — |
| 14 | JPMORGAN CHASE & CO | 2.00 +— (+0.0%) | 11.00 +3.0 (+37.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.50 -56.6% | 6 qtrs — |
| 15 | CITIGROUP INC | 1.00 +1.0 (+100.0%) | 5.00 +5.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.00 +8.4% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 90.3K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 35.63 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 97.83 | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 7.23 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 16.6K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 36.50 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 20.03 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 8.00 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 0.86 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 0.13 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
1.73M
Cash buys
—
Cash sales
3.00
Net activity
-1,734,386
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 8 | 4.08 | 32.64 | 301 | D | ↗ |
| 2026-01-21 | Exicure HiTron Inc. | 10% Owner | S-Sale | D | Common Stock | 258,367 | 4.50 | 1.16M | 1,598,947 | D | ↗ |
| 2026-01-16 | Exicure HiTron Inc. | 10% Owner | S-Sale | D | Common | 734,747 | 4.50 | 3.31M | 1,857,314 | D | ↗ |
| 2026-01-07 | Exicure HiTron Inc. | 10% Owner | S-Sale | D | Common | 741,272 | 4.50 | 3.34M | 2,592,061 | D | ↗ |
| 2025-12-08 | SANGSANGIN INVESTMENT & SECURITIES CO., LTD. | 10% Owner | S-Sale | D | Common Stock | 433,332 | 8.71 | 3.77M | 0 | D | ↗ |
| 2025-11-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 7 | 3.71 | 25.97 | 309 | D | ↗ |
| 2025-09-08 | Yeo Sangjin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-08 | Hwang Aejin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 9 | 6.65 | 59.85 | 316 | D | ↗ |
| 2025-05-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 8 | 10.06 | 80.48 | 325 | D | ↗ |
| 2025-02-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 9 | 10.03 | 90.27 | 333 | D | ↗ |
| 2024-12-26 | HiTron Systems Inc. | 10% Owner | P-Purchase | A | Common Stock | 2,900,000 | 3.00 | 8.70M | 3,333,333 | D | ↗ |
| 2024-12-19 | Song Sang Wook | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-19 | Kang Min Woo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-19 | John Ho Jung | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-19 | Choi Chang Keun | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-12 | SANGSANGIN INVESTMENT & SECURITIES CO., LTD. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 433,332 | D | ↗ |
| 2024-11-21 | Yoo Andy | Director / Officer | — | — | Common Stock | 0 | 0.00 | — | 73,666 | I | ↗ |
| 2024-11-21 | HiTron Systems Inc. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 433,333 | D | ↗ |
| 2024-11-21 | Baik Seung Ik | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 7 | 2.90 | 20.30 | 342 | D | ↗ |
| 2024-09-12 | DGP Co., Ltd. | 10% Owner | P-Purchase | A | Common Stock | 237,223 | 3.00 | 711.7K | 849,223 | — | ↗ |
| 2024-08-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 38 | 0.36 | 13.68 | 1,743 | — | ↗ |
| 2024-05-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 46 | 0.52 | 23.87 | 1,781 | — | ↗ |
| 2024-02-29 | DGP Co., Ltd. | 10% Owner | S-Sale | D | Common Stock | 3,400,000 | 1.32 | 4.49M | 0 | — | ↗ |
| 2024-02-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 46 | 0.60 | 27.50 | 1,827 | — | ↗ |
| 2023-11-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 38 | 0.57 | 21.47 | 1,873 | — | ↗ |
| 2023-09-26 | Eom Minhee | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-21 | Lee Hojoon | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-21 | Lee Dongho | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-21 | Ko Hyuk Joon | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 37 | 0.83 | 30.71 | 1,911 | — | ↗ |
| 2023-06-23 | DGP Co., Ltd. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,400,000 | — | ↗ |
| 2023-06-23 | CBI USA, Inc. | 10% Owner | C-Conversion | D | Common Stock | 3,400,000 | 1.60 | 5.44M | 818,299 | — | ↗ |
| 2023-05-16 | Miller Josh | Officer | F-InKind | D | Common Stock | 185 | 1.07 | 198.47 | 1,948 | — | ↗ |
| 2023-05-03 | Miller Josh | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,133 | — | ↗ |
| 2023-04-26 | Miller Josh | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-26 | Kim Jung Sang | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-26 | Hwang Jiyoung | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-27 | Shin Seung Soo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-27 | Jo Cheolho | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-24 | Sung Uh Kang Paul | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-24 | Lee Hyukku | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-24 | Ahn Changil | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-22 | CBI USA, Inc. | 10% Owner | J-Other | D | CBI USA, Inc. 1st Bearer-type Interest Unsecured Private | 5,440,000 | 1.60 | 8.70M | 5,440,000 | — | ↗ |
| 2023-01-04 | Hwang Jiyoung | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-12-30 | Hwang Jiyoung | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-12-15 | CBI USA, Inc. | Director | P-Purchase | A | Common Stock | 3,400,000 | 1.60 | 5.44M | 4,218,299 | — | ↗ |
| 2022-06-13 | SULAT JAMES R | Director | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-13 | Muralidhar Bali | Director | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-13 | GAROFALO ELIZABETH A. | Director | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.13 | 6.3K | 50,000 | — | ↗ |
| 2022-06-13 | Cleland Jeffrey L | Director | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-05-19 | Muralidhar Bali | Director | P-Purchase | A | Common Stock | 1,472,126 | 0.19 | 285.2K | 8,449,126 | — | ↗ |
| 2022-05-19 | CBI USA, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 24,548,985 | — | ↗ |
| 2022-05-16 | SCHROFF MATTHIAS | Officer | A-Award | A | Employee Stock Option (right to buy) | 2,324,550 | 0.00 | — | 2,324,550 | — | ↗ |
| 2022-05-16 | Papadimas Elias D. | Officer | A-Award | A | Employee Stock Option (right to buy) | 424,000 | 0.00 | — | 424,000 | — | ↗ |
| 2022-05-16 | Longoria Sarah | Officer | A-Award | A | Employee Stock Option (right to buy) | 180,750 | 0.00 | — | 180,750 | — | ↗ |
| 2022-03-07 | Longoria Sarah | Officer | — | D | Employee Stock Option (right to buy) | 125,000 | 0.18 | 23.0K | 0 | — | ↗ |
| 2021-12-21 | Gates Frontier, LLC | 10% Owner | S-Sale | D | Common stock | 1,268,619 | 0.24 | 303.2K | 5,064,703 | — | ↗ |
| 2021-11-15 | Giljohann David A | Director / Officer | A-Award | A | Common Stock | 7,500 | 0.91 | 6.8K | 38,666 | — | ↗ |
| 2021-11-15 | Feltner Douglas E. | Officer | A-Award | A | Common Stock | 7,500 | 0.91 | 6.8K | 15,000 | — | ↗ |
| 2021-08-27 | Papadimas Elias D. | Officer | P-Purchase | A | Common Stock | 10,000 | 1.38 | 13.8K | 10,000 | — | ↗ |
| 2021-06-02 | Walbert Timothy P | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.71 | 85.5K | 50,000 | — | ↗ |
| 2021-06-02 | SULAT JAMES R | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.71 | 85.5K | 50,000 | — | ↗ |
| 2021-06-02 | SASSINE ANDY | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.71 | 85.5K | 50,000 | — | ↗ |
| 2021-06-02 | Muralidhar Bali | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.71 | 85.5K | 50,000 | — | ↗ |
| 2021-06-02 | Hau Bosun | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.71 | 85.5K | 50,000 | — | ↗ |
| 2021-06-02 | GAROFALO ELIZABETH A. | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.71 | 85.5K | 50,000 | — | ↗ |
| 2021-06-02 | Cleland Jeffrey L | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.71 | 85.5K | 50,000 | — | ↗ |
| 2021-06-01 | Papadimas Elias D. | Officer | — | D | Employee Stock Option (right to buy) | 4,964 | 4.21 | 20.9K | 0 | — | ↗ |
| 2021-05-14 | SCHROFF MATTHIAS | Officer | A-Award | A | Common Stock | 7,500 | 1.27 | 9.5K | 7,500 | — | ↗ |
| 2021-05-14 | Giljohann David A | Director / Officer | A-Award | A | Common Stock | 7,500 | 1.27 | 9.5K | 31,166 | — | ↗ |
| 2021-05-14 | Feltner Douglas E. | Officer | A-Award | A | Common Stock | 7,500 | 1.27 | 9.5K | 7,500 | — | ↗ |
| 2021-05-13 | Bock Brian | Officer | A-Award | A | Employee Stock Option (right to buy) | 600,000 | 1.54 | 924.0K | 600,000 | — | ↗ |
| 2021-04-27 | SCHROFF MATTHIAS | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,000 | 1.90 | 114.0K | 60,000 | — | ↗ |
| 2021-04-27 | Giljohann David A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,142,900 | 1.90 | 2.17M | 1,142,900 | — | ↗ |
| 2021-04-27 | Feltner Douglas E. | Officer | A-Award | A | Employee Stock Option (right to buy) | 220,000 | 1.90 | 418.0K | 220,000 | — | ↗ |
| 2021-03-05 | SASSINE ANDY | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 2.06 | 206.0K | 100,000 | — | ↗ |
| 2021-03-05 | GAROFALO ELIZABETH A. | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 2.06 | 206.0K | 100,000 | — | ↗ |
| 2021-01-02 | SULAT JAMES R | Director | A-Award | A | Stock Option (right to buy) | 43,386 | 1.82 | 79.0K | 43,386 | — | ↗ |
| 2020-07-06 | Venkatesan Jay | Director | M-Exempt | A | Common Stock | 12,930 | 1.03 | 13.3K | 324,473 | — | ↗ |
| 2020-06-12 | Mirkin Chad A. | Director / 10% Owner | S-Sale | D | Common Stock | 10,195 | 2.83 | 28.9K | 11,257,629 | — | ↗ |
| 2020-06-12 | AURASENSE LLC | 10% Owner | S-Sale | D | Common Stock | 10,195 | 2.83 | 28.9K | 11,257,629 | — | ↗ |
| 2020-06-04 | Walbert Timothy P | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.79 | 60.5K | 21,693 | — | ↗ |
| 2020-06-04 | WALT DAVID R | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.79 | 60.5K | 21,693 | — | ↗ |
| 2020-06-04 | Venkatesan Jay | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.79 | 60.5K | 21,693 | — | ↗ |
| 2020-06-04 | Muralidhar Bali | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.79 | 60.5K | 21,693 | — | ↗ |
| 2020-06-04 | Mirkin Chad A. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 21,693 | 2.79 | 60.5K | 21,693 | — | ↗ |
| 2020-06-04 | Kim Helen Susan | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.79 | 60.5K | 21,693 | — | ↗ |
| 2020-06-04 | Hau Bosun | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.79 | 60.5K | 21,693 | — | ↗ |
| 2020-06-04 | Cleland Jeffrey L | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.79 | 60.5K | 21,693 | — | ↗ |
| 2020-06-03 | Feltner Douglas E. | Officer | A-Award | A | Employee Stock Option (right to buy) | 400,000 | 2.72 | 1.09M | 400,000 | — | ↗ |
| 2020-05-20 | Mirkin Chad A. | Director / 10% Owner | M-Exempt | A | Common Stock | 49,649 | 0.65 | 32.3K | 64,649 | — | ↗ |
| 2020-03-13 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 291,066 | 1.21 | 352.9K | 2,058,777 | — | ↗ |
| 2020-03-13 | SNYDER DAVID S | Officer | A-Award | A | Employee Stock Option (right to buy) | 230,200 | 1.19 | 273.9K | 230,200 | — | ↗ |
| 2020-03-13 | Giljohann David A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 871,504 | 1.19 | 1.04M | 871,504 | — | ↗ |
| 2020-03-12 | SNYDER DAVID S | Officer | P-Purchase | A | Common Stock | 18,248 | 1.40 | 25.6K | 18,248 | — | ↗ |
| 2020-03-12 | Mirkin Chad A. | Director / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 1.45 | 21.8K | 15,000 | — | ↗ |
| 2019-12-19 | Muralidhar Bali | Director | P-Purchase | A | Common Stock $0.0001 par value | 727,000 | 2.75 | 2.00M | 6,977,000 | — | ↗ |
| 2019-08-02 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 1,000,000 | 2.00 | 2.00M | 1,767,711 | — | ↗ |
| 2019-08-02 | Venkatesan Jay | Director | P-Purchase | A | Common Stock | 250,000 | 2.00 | 500.0K | 302,234 | — | ↗ |
| 2019-08-02 | Muralidhar Bali | Director | A-Award | A | Stock option (right to buy) | 43,386 | 2.95 | 128.0K | 43,386 | — | ↗ |
| 2019-08-02 | Mirkin Chad A. | Director / 10% Owner | P-Purchase | A | Common Stock | 25,000 | 2.00 | 50.0K | 25,000 | — | ↗ |
| 2019-08-02 | Hau Bosun | Director | A-Award | A | Stock Option (right to buy) | 43,386 | 2.95 | 128.0K | 43,386 | — | ↗ |
| 2019-07-22 | Walbert Timothy P | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-22 | Cleland Jeffrey L | Director | A-Award | A | Stock Option (right to buy) | 43,386 | 2.32 | 100.7K | 43,386 | — | ↗ |
| 2019-06-14 | WALT DAVID R | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.78 | 60.3K | 21,693 | — | ↗ |
| 2019-06-14 | Venkatesan Jay | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.78 | 60.3K | 21,693 | — | ↗ |
| 2019-06-14 | Thaxton Colby Shad | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.78 | 60.3K | 21,693 | — | ↗ |
| 2019-06-14 | Mirkin Chad A. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 21,693 | 2.78 | 60.3K | 21,693 | — | ↗ |
| 2019-06-14 | Kim Helen Susan | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 2.78 | 60.3K | 21,693 | — | ↗ |
| 2019-03-22 | Mirkin Chad A. | Director / 10% Owner | P-Purchase | A | Common Stock | 500 | 2.30 | 1.2K | 27,267 | — | ↗ |
| 2019-03-21 | Mirkin Chad A. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 2.43 | 2.4K | 26,767 | — | ↗ |
| 2019-03-19 | Giljohann David A | Director / Officer | P-Purchase | A | Common Stock | 7,000 | 2.40 | 16.8K | 23,666 | — | ↗ |
| 2019-03-18 | Mirkin Chad A. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 2.40 | 2.4K | 25,767 | — | ↗ |
| 2019-03-13 | Mirkin Chad A. | Director / 10% Owner | P-Purchase | A | Common Stock | 2,200 | 2.50 | 5.5K | 24,767 | — | ↗ |
| 2019-02-28 | SNYDER DAVID S | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 2.80 | 700.0K | 250,000 | — | ↗ |
| 2018-08-02 | SNYDER DAVID S | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 4.97 | 497.0K | 100,000 | — | ↗ |
| 2018-06-19 | WALT DAVID R | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 5.82 | 126.3K | 21,693 | — | ↗ |
| 2018-06-19 | Venkatesan Jay | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 5.82 | 126.3K | 21,693 | — | ↗ |
| 2018-06-19 | Thaxton Colby Shad | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 5.82 | 126.3K | 21,693 | — | ↗ |
| 2018-06-19 | Mirkin Chad A. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 21,693 | 5.82 | 126.3K | 21,693 | — | ↗ |
| 2018-06-19 | Kim Helen Susan | Director | A-Award | A | Stock Option (right to buy) | 21,693 | 5.82 | 126.3K | 21,693 | — | ↗ |
| 2018-04-26 | SCHROFF MATTHIAS | Officer | A-Award | A | Employee Stock Option (right to buy) | 345,000 | 3.00 | 1.04M | 345,000 | — | ↗ |
| 2018-04-16 | SCHROFF MATTHIAS | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-26 | WALT DAVID R | Director | P-Purchase | A | Common Stock | 268,333 | 3.00 | 805.0K | 767,711 | — | ↗ |
| 2017-09-26 | Venkatesan Jay | Director | J-Other | A | Common Stock | 190,957 | 0.00 | — | 190,957 | — | ↗ |
| 2017-09-26 | Tompkins Mark N. | — | P-Purchase | A | Common Stock | 166,667 | 3.00 | 500.0K | 1,825,667 | — | ↗ |
| 2017-09-26 | Thaxton Colby Shad | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-26 | SNYDER DAVID S | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-26 | Mirkin Chad A. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 24,824 | 4.21 | 104.5K | 24,824 | — | ↗ |
| 2017-09-26 | Kim Helen Susan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-26 | Kandimalla Ekambarswara R | Officer | A-Award | A | Employee Stock Option (right to buy) | 281,915 | 1.98 | 558.2K | 281,915 | — | ↗ |
| 2017-09-26 | Giljohann David A | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-26 | Gates Ventures, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 6,333,322 | — | ↗ |
| 2017-09-26 | AURASENSE LLC | 10% Owner | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 11,267,824 | — | ↗ |
| 2017-09-22 | Tompkins Mark N. | Director / 10% Owner | A-Award | A | Common Stock | 659,000 | 0.00 | — | 1,659,000 | — | ↗ |
| 2017-09-22 | Jacobs Ian Seth | Director / Officer | A-Award | A | Common Stock | 38,160 | 0.00 | — | 103,160 | — | ↗ |
| 2017-06-15 | Tompkins Mark N. | Director / 10% Owner | P-Purchase | A | Common Stock | 35,000 | 0.03 | 875.00 | 1,000,000 | — | ↗ |
| 2017-06-15 | Jacobs Ian Seth | Director / Officer | S-Sale | D | Common Stock | 35,000 | 0.03 | 875.00 | 65,000 | — | ↗ |
| 2017-05-20 | Tompkins Mark N. | Director / 10% Owner | — | D | Common Shares, par value $0.0001 per share | 0 | 0.00 | — | 900,000 | — | ↗ |
| 2017-05-20 | Jacobs Ian Seth | Director / Officer / 10% Owner | — | D | Common Shares, par value $0.0001 per share | 0 | 0.00 | — | 100,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
6.37M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Jiyoung Hwang Former Chief Financial Officer | 150.0K | — | — | — | — | 20.0K | 170.0K | 0.00% | ↗ |
| 2 | 2024 | Paul Kang Former Chief Executive Officer | 150.0K | — | — | — | — | 20.0K | 170.0K | 0.00% | ↗ |
| 3 | 2024 | Andy Yoo Chief Executive Officer | 25.0K | — | — | — | — | 2.2K | 27.2K | 0.00% | ↗ |
| 4 | 2024 | Seung Ik Baik Chief Financial Officer | 3.6K | — | — | — | — | 2.2K | 5.8K | 0.00% | ↗ |
| 5 | 2023 | Matthias G. Schroff, Ph.D. Former Chief Executive Officer | 183.3K | 603.8K | — | — | — | 10.3K | 797.5K | 0.00% | ↗ |
| 6 | 2023 | Elias D. Papadimas Former Chief Financial Officer | 135.0K | 370.0K | — | — | — | 11.3K | 516.3K | 0.00% | ↗ |
| 7 | 2023 | Sarah Longoria Chief Human Resources and Compliance Officer | 125.0K | 370.0K | — | — | — | 11.3K | 506.3K | 0.00% | ↗ |
| 8 | 2023 | Jung Sang (Michael) Kim Former Chief Executive Officer | 90.6K | — | — | — | — | 313.00 | 90.9K | 0.00% | ↗ |
| 9 | 2023 | Paul Kang Chief Executive Officer | 50.0K | — | — | — | — | — | 50.0K | 0.00% | ↗ |
| 10 | 2023 | Paul Kang Former Chief Executive Officer | 50.0K | — | — | — | — | — | 50.0K | 0.00% | ↗ |
| 11 | 2023 | Jiyoung Hwang Former Chief Financial Officer | 49.4K | — | — | — | — | — | 49.4K | 0.00% | ↗ |
| 12 | 2022 | Matthias G. Schroff, Ph.D. Former Chief Executive Officer | 538.2K | 122.2K | 267.3K | 277.8K | — | 12.3K | 1.22M | 44.76% | ↗ |
| 13 | 2022 | Elias D. Papadimas Former Chief Financial Officer | 400.6K | 140.0K | 48.8K | 67.1K | — | 10.3K | 666.8K | 17.38% | ↗ |
| 14 | 2022 | Sarah Longoria Chief Human Resources and Compliance Officer | 300.0K | 99.8K | 20.8K | 26.1K | — | — | 446.7K | 10.50% | ↗ |
| 15 | 2021 | David A. Giljohann, Ph.D. Former Chief Executive Officer and Former Chief Technology Officer | 560.6K | — | — | 1.52M | — | 9.8K | 2.09M | 72.72% | ↗ |
| 16 | 2021 | Matthias G. Schroff, Ph.D. Chief Executive Officer and Former Chief Operating Officer and Chief Scientific Officer | 449.1K | 17.8K | — | 713.1K | — | 12.2K | 1.19M | 59.82% | ↗ |
| 17 | 2021 | Brian C. Bock Former Chief Executive Officer and Former Chief Financial Officer | 269.8K | 134.7K | — | 9.00 | — | 44.8K | 929.3K | 0.00% | ↗ |
| 18 | 2021 | Douglas E. Feltner, M.D. Former Chief Medical Officer | 409.2K | — | — | 292.6K | — | 12.3K | 714.1K | 40.98% | ↗ |
| 19 | 2020 | David A. Giljohann, Ph.D. Chief Executive Officer and Interim Chief Financial Officer | 560.8K | — | — | 725.4K | 265.8K | 9.8K | 1.56M | 46.45% | ↗ |
| 20 | 2020 | David A. Giljohann, Ph.D. Former Chief Executive Officer and Former Chief Technology Officer | 560.8K | — | — | 725.4K | 265.8K | 9.8K | 1.56M | 46.45% | ↗ |
| 21 | 2020 | Douglas E. Feltner, M.D. Former Chief Medical Officer | 239.9K | — | — | 770.5K | 63.5K | — | 1.07M | 71.75% | ↗ |
| 22 | 2020 | Douglas E. Feltner, M.D. Chief Medical Officer | 239.9K | — | — | 770.5K | 63.5K | — | 1.07M | 71.75% | ↗ |
| 23 | 2020 | Matthias G. Schroff, Ph.D. Chief Operating Officer | 375.0K | — | — | — | 138.0K | 12.3K | 525.3K | 0.00% | ↗ |
| 24 | 2020 | Matthias G. Schroff, Ph.D. Chief Executive Officer and Former Chief Operating Officer and Chief Scientific Officer | 375.0K | — | — | — | 138.0K | 12.3K | 525.3K | 0.00% | ↗ |
| 25 | 2019 | David S. Snyder Chief Financial Officer and Secretary | 399.8K | — | — | 501.6K | 166.7K | 12.3K | 1.08M | 46.43% | ↗ |
| 26 | 2019 | David A. Giljohann, Ph.D. Chief Executive Officer and Interim Chief Financial Officer | 538.5K | — | — | — | 237.5K | 9.5K | 785.5K | 0.00% | ↗ |
| 27 | 2019 | David A. Giljohann, Ph.D. Chief Executive Officer | 538.5K | — | — | — | 237.5K | 9.5K | 785.5K | 0.00% | ↗ |
| 28 | 2019 | Matthias G. Schroff, Ph.D. Chief Operating Officer | 375.0K | — | — | — | 89.1K | 12.3K | 476.3K | 0.00% | ↗ |
| 29 | 2018 | Matthias G. Schroff, Ph.D. Chief Operating Officer | 206.3K | — | — | 717.5K | 48.5K | 62.3K | 1.03M | 69.36% | ↗ |
| 30 | 2018 | David S. Snyder Chief Financial Officer and Secretary | 321.8K | — | — | 344.8K | 132.9K | 4.7K | 804.2K | 42.87% | ↗ |
| 31 | 2018 | David S. Snyder Chief Financial Officer | 321.8K | — | — | 344.8K | 132.9K | 4.7K | 804.2K | 42.87% | ↗ |
| 32 | 2018 | David A. Giljohann, Ph.D. Chief Executive Officer | 359.8K | — | — | — | 164.5K | — | 524.3K | 0.00% | ↗ |
| 33 | 2018 | Ekambar Kandimalla, Ph.D. Chief Scientific Officer | 267.8K | — | — | — | — | 5.6K | 273.4K | 0.00% | ↗ |
| 34 | 2017 | David A. Giljohann, Ph.D. Chief Executive Officer | 363.1K | — | — | 1.46M | 148.8K | — | 1.97M | 74.02% | ↗ |
| 35 | 2017 | David S. Snyder Chief Financial Officer | 314.3K | — | — | 36.4K | 94.3K | — | 445.0K | 8.19% | ↗ |
| 36 | 2017 | Ekambar Kandimalla, Ph.D. Chief Scientific Officer | 267.8K | — | — | — | 67.0K | 50.0K | 384.8K | 0.00% | ↗ |
| 37 | 2016 | David S. Snyder Chief Financial Officer | 314.3K | — | — | — | 62.9K | — | 377.1K | 0.00% | ↗ |
| 38 | 2016 | David A. Giljohann, Ph.D. Chief Executive Officer | 257.5K | — | — | — | 82.4K | 9.8K | 349.7K | 0.00% | ↗ |
| 39 | 2016 | Ekambar Kandimalla, Ph.D. Chief Scientific Officer | 267.8K | — | — | — | — | 2.9K | 270.7K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jungsoo Kim | Chief Executive Officer, President & Director | 777.2K | male |
| Devki Sukhtankar | Head of Preclinical Research & Translational Medicine | — | — |
| Gyuyeob Lee | Interim CFO & Secretary | — | male |
| Joshua Miller | Chief Accounting Officer | — | male |
| Niña Caculitan | Head of Clinical | — | — |
| Young Seung Ko | Chief Operating Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XCUR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
